JP2021038251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021038251A5 JP2021038251A5 JP2020193338A JP2020193338A JP2021038251A5 JP 2021038251 A5 JP2021038251 A5 JP 2021038251A5 JP 2020193338 A JP2020193338 A JP 2020193338A JP 2020193338 A JP2020193338 A JP 2020193338A JP 2021038251 A5 JP2021038251 A5 JP 2021038251A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutical
- eye
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 84
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 16
- 229960003744 loteprednol etabonate Drugs 0.000 claims 16
- 229920000428 triblock copolymer Polymers 0.000 claims 16
- 239000002245 particle Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 239000007771 core particle Substances 0.000 claims 13
- 239000002105 nanoparticle Substances 0.000 claims 13
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 11
- 229920001992 poloxamer 407 Polymers 0.000 claims 7
- 229940044476 poloxamer 407 Drugs 0.000 claims 7
- 239000000725 suspension Substances 0.000 claims 7
- 239000011248 coating agent Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 4
- 229950009769 etabonate Drugs 0.000 claims 4
- 210000003097 mucus Anatomy 0.000 claims 4
- 229920001983 poloxamer Polymers 0.000 claims 4
- 229960000502 poloxamer Drugs 0.000 claims 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 3
- 239000004793 Polystyrene Substances 0.000 claims 3
- 210000003756 cervix mucus Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000004682 mucosal barrier function Effects 0.000 claims 3
- 229920001451 polypropylene glycol Polymers 0.000 claims 3
- 229920002223 polystyrene Polymers 0.000 claims 3
- -1 thixocorticoid Chemical compound 0.000 claims 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 2
- 206010015943 Eye inflammation Diseases 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000002296 dynamic light scattering Methods 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 claims 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- UFICVEHDQUKCEA-UHFFFAOYSA-N N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide Chemical compound CN1C=NC(C=2SC3=C(OC=4C(=CC(NC(=S)NC(=O)CC=5C=CC=CC=5)=CC=4)F)C=CN=C3C=2)=C1 UFICVEHDQUKCEA-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 229920002517 Poloxamer 338 Polymers 0.000 claims 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 229960003099 amcinonide Drugs 0.000 claims 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims 1
- 210000001742 aqueous humor Anatomy 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 229940119740 deoxycorticosterone Drugs 0.000 claims 1
- 229960003662 desonide Drugs 0.000 claims 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims 1
- 229960002593 desoximetasone Drugs 0.000 claims 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229940087410 dexasone Drugs 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229960002011 fludrocortisone Drugs 0.000 claims 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 1
- 229960000618 fluprednisolone Drugs 0.000 claims 1
- 229950007540 glesatinib Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229960002383 halcinonide Drugs 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229950002216 linifanib Drugs 0.000 claims 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 239000002395 mineralocorticoid Substances 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 229940106032 poloxamer 335 Drugs 0.000 claims 1
- 229960002800 prednisolone acetate Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642261P | 2012-05-03 | 2012-05-03 | |
| US201261642313P | 2012-05-03 | 2012-05-03 | |
| US61/642,261 | 2012-05-03 | ||
| US61/642,313 | 2012-05-03 | ||
| US201261738949P | 2012-12-18 | 2012-12-18 | |
| US61/738,949 | 2012-12-18 | ||
| US201361784701P | 2013-03-14 | 2013-03-14 | |
| US61/784,701 | 2013-03-14 | ||
| JP2019182856A JP2020015758A (ja) | 2012-05-03 | 2019-10-03 | 改善された粘膜輸送を示す医薬用ナノ粒子 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182856A Division JP2020015758A (ja) | 2012-05-03 | 2019-10-03 | 改善された粘膜輸送を示す医薬用ナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021038251A JP2021038251A (ja) | 2021-03-11 |
| JP2021038251A5 true JP2021038251A5 (enExample) | 2021-05-06 |
| JP7372897B2 JP7372897B2 (ja) | 2023-11-01 |
Family
ID=48464113
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510490A Active JP6720443B2 (ja) | 2012-05-03 | 2013-05-03 | 改善された粘膜輸送を示す医薬用ナノ粒子 |
| JP2019182856A Pending JP2020015758A (ja) | 2012-05-03 | 2019-10-03 | 改善された粘膜輸送を示す医薬用ナノ粒子 |
| JP2020193338A Active JP7372897B2 (ja) | 2012-05-03 | 2020-11-20 | 改善された粘膜輸送を示す医薬用ナノ粒子 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510490A Active JP6720443B2 (ja) | 2012-05-03 | 2013-05-03 | 改善された粘膜輸送を示す医薬用ナノ粒子 |
| JP2019182856A Pending JP2020015758A (ja) | 2012-05-03 | 2019-10-03 | 改善された粘膜輸送を示す医薬用ナノ粒子 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20130316001A1 (enExample) |
| EP (1) | EP2844223A1 (enExample) |
| JP (3) | JP6720443B2 (enExample) |
| KR (2) | KR20150006869A (enExample) |
| CN (5) | CN104661647A (enExample) |
| AU (3) | AU2013256092B2 (enExample) |
| BR (1) | BR112014027296B1 (enExample) |
| CA (1) | CA2871748C (enExample) |
| CL (3) | CL2014002956A1 (enExample) |
| HK (2) | HK1208161A1 (enExample) |
| MX (2) | MX373352B (enExample) |
| NZ (5) | NZ741873A (enExample) |
| WO (1) | WO2013166436A1 (enExample) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| WO2013110028A1 (en) | 2012-01-19 | 2013-07-25 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| US8962577B2 (en) | 2012-03-16 | 2015-02-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| EP2825207B1 (en) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US20130316001A1 (en) * | 2012-05-03 | 2013-11-28 | Kala Pharmaceuticals, Inc. | Particles, compositions and methods for ophthalmic and/or other applications |
| US10864219B2 (en) * | 2012-05-03 | 2020-12-15 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2013166385A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| WO2013166408A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| HK1208377A1 (en) | 2012-05-04 | 2016-03-04 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| AU2014227737B2 (en) | 2013-03-15 | 2018-05-17 | KALA BIO, Inc. | Meropenem derivatives and uses thereof |
| SG10201604814WA (en) | 2013-03-21 | 2016-08-30 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
| JP2016518388A (ja) | 2013-04-30 | 2016-06-23 | オティトピック インク． | 乾燥粉末配合および使用方法 |
| HK1223307A1 (zh) | 2013-05-30 | 2017-07-28 | Kala Pharmaceuticals, Inc. | 新型化合物和其用途 |
| CN108530458A (zh) | 2013-11-01 | 2018-09-14 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
| WO2015127368A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic microbicidal formulations and methods of use |
| EP3110804A4 (en) | 2014-02-25 | 2017-11-22 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders |
| SG11201608729RA (en) * | 2014-05-01 | 2016-11-29 | Integral Biosystems Llc | Membrane-adherent self-assembled systems for treatment of ocular disorders |
| KR101501217B1 (ko) * | 2014-07-17 | 2015-03-10 | 최명 | 필러용 폴리디옥사논 입자의 제조방법 |
| US10172852B2 (en) | 2014-07-28 | 2019-01-08 | Sun Pharma Advanced Research Company Ltd. | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| WO2016025215A1 (en) * | 2014-08-13 | 2016-02-18 | The Johns Hopkins University | Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization |
| AU2015329609B2 (en) * | 2014-10-09 | 2021-01-21 | Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. | Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases |
| US20170239330A1 (en) * | 2014-10-15 | 2017-08-24 | Rapid Pathogen Screening, Inc. | Formulations for histatin therapeutics |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| WO2016083891A1 (en) | 2014-11-25 | 2016-06-02 | Eyal Sheetrit | Compositions and methods for delivering a bio-active agent or bio-active agents |
| US10253045B2 (en) | 2014-11-26 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
| EP3230272B1 (en) | 2014-12-10 | 2020-08-19 | Kala Pharmaceuticals, Inc. | 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof |
| WO2016094617A1 (en) * | 2014-12-11 | 2016-06-16 | Phosphorex, Inc. | Aqueous topical drug formulation with controlled release and increased stability |
| JP6882186B2 (ja) * | 2014-12-15 | 2021-06-02 | ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ | スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 |
| US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
| US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| EP3250184B1 (en) | 2015-01-27 | 2024-12-18 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| KR101730399B1 (ko) | 2015-04-13 | 2017-04-27 | 영남대학교 산학협력단 | 악시티닙을 포함하는 약물 전달체 및 이의 제조방법 |
| KR20240034866A (ko) | 2015-06-06 | 2024-03-14 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
| TWI700085B (zh) * | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
| KR101778004B1 (ko) * | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
| US10729663B1 (en) * | 2015-08-21 | 2020-08-04 | University Of South Florida | Nanoparticles in thermoreversible gels for enhanced therapeutics |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| EP3352749A4 (en) | 2015-09-22 | 2019-09-04 | Graybug Vision, Inc. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
| US10036135B2 (en) * | 2015-10-23 | 2018-07-31 | Philip S. Dunlap | Methods and systems to contain pollution and hazardous environments (CPHE) |
| PT3206672T (pt) | 2015-10-27 | 2018-06-20 | Eupraxia Pharmaceuticals Inc | Formulações de libertação prolongada de anestésicos locais |
| US10668025B2 (en) * | 2015-10-30 | 2020-06-02 | The Johns Hopkins University | Mucus penetrating particles with high molecular weight and dense coatings |
| HK1257499A1 (zh) | 2015-11-12 | 2019-10-25 | Graybug Vision, Inc. | 用於治疗的聚集性微粒 |
| WO2017210132A1 (en) | 2016-06-02 | 2017-12-07 | Cloudbreak Therapeutics, Llc | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization |
| RS63136B9 (sr) * | 2016-09-13 | 2022-10-31 | Kyowa Kirin Co Ltd | Lekoviti sastav koji sadrži tivozanib |
| CA3037174A1 (en) * | 2016-09-16 | 2018-03-22 | Kala Pharmaceuticals, Inc. | Particles, compositions, and methods for ophthalmic and/or other applications |
| US20190216726A1 (en) * | 2016-09-16 | 2019-07-18 | Kala Pharmaceuticals, Inc. | Particles, Compositions and Methods for Ophthalmic and/or Other Applications |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| KR102632860B1 (ko) | 2017-03-01 | 2024-02-02 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물 |
| WO2018175268A1 (en) * | 2017-03-19 | 2018-09-27 | Biohealthways, Inc. | Biodegrading implantable ocular sustained release drug delivery system |
| CN110662543A (zh) | 2017-03-23 | 2020-01-07 | 灰色视觉公司 | 用于治疗眼部疾病的药物和组合物 |
| EP3621656B1 (en) * | 2017-05-08 | 2023-11-29 | Inmed Pharmaceuticals Inc. | Ocular drug delivery formulation |
| MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA |
| WO2019055028A1 (en) * | 2017-09-15 | 2019-03-21 | Kala Pharmaceuticals, Inc. | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| KR102507987B1 (ko) | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
| US11512147B2 (en) | 2017-11-15 | 2022-11-29 | Chugai Seiyaku Kabushiki Kaisha | Hyaluronic acid derivative modified with polyethylene glycol |
| CN111712468A (zh) | 2017-12-22 | 2020-09-25 | 北卡罗莱纳州立大学 | 聚合物荧光团、包含其的组合物及制备和使用其的方法 |
| US11090236B2 (en) * | 2018-05-02 | 2021-08-17 | Ocusoft, Inc. | Hypochlorous acid-based eyelid cleansers |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| AU2019336238A1 (en) | 2018-09-06 | 2021-04-08 | Achillion Pharmaceuticals, Inc. | Morphic forms of Complement factor D inhibitors |
| WO2020069024A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| CN110664757B (zh) * | 2018-11-19 | 2022-08-02 | 成都瑞沐生物医药科技有限公司 | 纳米晶滴眼剂、其制备方法及其应用 |
| EP3898617A4 (en) | 2018-12-17 | 2022-08-17 | Achillion Pharmaceuticals, Inc. | TARGETED DOSAGE FOR THE TREATMENT OF COMPLEMENT INDUCED DISORDERS |
| US12479856B2 (en) | 2019-03-22 | 2025-11-25 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| US20230190725A1 (en) * | 2019-04-29 | 2023-06-22 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
| WO2021011753A1 (en) * | 2019-07-16 | 2021-01-21 | The Regents Of The University Of Michigan | Composite drug particles and uses thereof |
| DK3962464T3 (da) * | 2019-10-01 | 2023-06-19 | Evonik Corp | Fremgangsmåde til fremstilling af nanopartikler i form af et pulver, der omfatter en bioresorberbar polyester |
| WO2021113637A1 (en) | 2019-12-04 | 2021-06-10 | Restore Vision, Llc. | Ophthalmic formulations for the treatment of presbyopia |
| WO2022231930A1 (en) | 2021-04-26 | 2022-11-03 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| CN113214419B (zh) * | 2021-05-06 | 2022-10-25 | 温州医科大学附属眼视光医院 | 一种乳糖酸修饰的聚2-溴乙基丙烯酸酯及其制备方法与应用 |
| CN113414049B (zh) * | 2021-06-04 | 2023-04-18 | 圣托马斯先进材料公司 | 一种智能雾化器及其使用方法 |
| US20230111190A1 (en) * | 2021-09-14 | 2023-04-13 | Nulixir Inc. | Oral compositions with improved bioavailability and methods of making the same |
| WO2023114375A2 (en) * | 2021-12-16 | 2023-06-22 | Alveolus Bio, Inc. | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease |
| WO2023141249A1 (en) * | 2022-01-24 | 2023-07-27 | Celanese Eva Performance Polymers Llc | Implantable device for delivery of a tyrosine kinase inhibitor |
| EP4509115A1 (en) * | 2022-03-31 | 2025-02-19 | Senju Usa, Inc. | Medical material |
| US20250332113A1 (en) * | 2022-06-01 | 2025-10-30 | The Trustees Of The University Of Pennsylvania | Adhesive particles for active delivery |
| US20240197691A1 (en) * | 2022-12-15 | 2024-06-20 | Cn2 Therapeutics, Inc. | Tacrolimus compositions and methods of use |
| WO2025146683A1 (en) | 2024-01-03 | 2025-07-10 | Lyotropic Delivery Systems Ltd. | Topical formulations for delivery of an active compound to the back of the eye |
| CN118217236B (zh) * | 2024-03-25 | 2025-04-11 | 山西锦波生物医药股份有限公司 | 一种含重组iii型人源化胶原蛋白的润眼液及制备方法 |
| CN118490657B (zh) * | 2024-05-15 | 2025-01-17 | 仁合熙德隆药业有限公司 | 瑞戈非尼片及其制备方法 |
| CN119097710B (zh) * | 2024-09-11 | 2025-09-02 | 山东大学齐鲁医院 | Ape1抑制剂在制备治疗过敏性鼻炎药物中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5619321B2 (enExample) * | 1971-09-22 | 1981-05-07 | ||
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| EP0996429B1 (en) * | 1997-10-27 | 2003-02-05 | MERCK PATENT GmbH | Solid state solutions and dispersions of poorly water soluble drugs |
| US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| JP2005531606A (ja) * | 2002-06-10 | 2005-10-20 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ステロール製剤およびステロールの組合せ |
| US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
| AU2004275594A1 (en) * | 2003-09-30 | 2005-04-07 | Solubest Ltd. | Water soluble nanoparticles inclusion complexes |
| WO2005065657A2 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
| CN101137700B (zh) * | 2005-03-09 | 2012-07-18 | 东丽株式会社 | 微粒及医药组合物 |
| DE102005011786A1 (de) * | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
| WO2007076448A2 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| CN101317847B (zh) * | 2007-06-06 | 2010-10-13 | 深圳市瑞谷医药技术有限公司 | 一种眼用或耳鼻用药物组合物及其用途 |
| CN101129385B (zh) * | 2007-08-14 | 2010-07-21 | 山东博士伦福瑞达制药有限公司 | 含加替沙星和依碳酸氯替泼诺的眼用组合物及其制备方法 |
| WO2009099942A2 (en) * | 2008-01-31 | 2009-08-13 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and uses thereof |
| TWI580441B (zh) * | 2008-09-19 | 2017-05-01 | 愛爾康研究有限公司 | 穩定的藥學次微米懸浮液及其形成方法 |
| BRPI1014854A2 (pt) * | 2009-03-30 | 2016-05-03 | Cerulean Pharma Inc | "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados" |
| EP2538929A4 (en) * | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE |
| WO2012054923A2 (en) * | 2010-10-22 | 2012-04-26 | Bind Biosciences, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
| EP2635254B1 (en) | 2010-11-05 | 2019-05-15 | The John Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| US20130316001A1 (en) | 2012-05-03 | 2013-11-28 | Kala Pharmaceuticals, Inc. | Particles, compositions and methods for ophthalmic and/or other applications |
-
2013
- 2013-05-03 US US13/886,658 patent/US20130316001A1/en not_active Abandoned
- 2013-05-03 BR BR112014027296-4A patent/BR112014027296B1/pt active IP Right Grant
- 2013-05-03 CN CN201380035493.6A patent/CN104661647A/zh active Pending
- 2013-05-03 CA CA2871748A patent/CA2871748C/en active Active
- 2013-05-03 US US13/886,602 patent/US20130316006A1/en not_active Abandoned
- 2013-05-03 AU AU2013256092A patent/AU2013256092B2/en active Active
- 2013-05-03 HK HK15108779.3A patent/HK1208161A1/xx unknown
- 2013-05-03 NZ NZ741873A patent/NZ741873A/en not_active IP Right Cessation
- 2013-05-03 CN CN202010551315.0A patent/CN111714472A/zh active Pending
- 2013-05-03 CN CN202010551342.8A patent/CN111700880A/zh active Pending
- 2013-05-03 KR KR1020147033577A patent/KR20150006869A/ko not_active Ceased
- 2013-05-03 HK HK15109260.7A patent/HK1208382A1/xx unknown
- 2013-05-03 CN CN202010551329.2A patent/CN111700879A/zh active Pending
- 2013-05-03 KR KR1020217002733A patent/KR102373259B1/ko active Active
- 2013-05-03 CN CN202010551316.5A patent/CN111700878A/zh active Pending
- 2013-05-03 EP EP13723629.5A patent/EP2844223A1/en active Pending
- 2013-05-03 NZ NZ728721A patent/NZ728721A/en not_active IP Right Cessation
- 2013-05-03 JP JP2015510490A patent/JP6720443B2/ja active Active
- 2013-05-03 NZ NZ742004A patent/NZ742004A/en not_active IP Right Cessation
- 2013-05-03 MX MX2014013315A patent/MX373352B/es active IP Right Grant
- 2013-05-03 NZ NZ742005A patent/NZ742005A/en not_active IP Right Cessation
- 2013-05-03 WO PCT/US2013/039540 patent/WO2013166436A1/en not_active Ceased
- 2013-05-03 NZ NZ700875A patent/NZ700875A/en not_active IP Right Cessation
-
2014
- 2014-10-30 CL CL2014002956A patent/CL2014002956A1/es unknown
- 2014-11-03 MX MX2020007227A patent/MX2020007227A/es unknown
-
2018
- 2018-02-20 AU AU2018201215A patent/AU2018201215B2/en active Active
- 2018-05-30 US US15/992,494 patent/US20180271782A1/en not_active Abandoned
-
2019
- 2019-10-03 JP JP2019182856A patent/JP2020015758A/ja active Pending
- 2019-11-25 CL CL2019003432A patent/CL2019003432A1/es unknown
- 2019-11-25 CL CL2019003433A patent/CL2019003433A1/es unknown
-
2020
- 2020-05-08 AU AU2020203052A patent/AU2020203052C1/en active Active
- 2020-07-31 US US16/945,398 patent/US20210052489A1/en not_active Abandoned
- 2020-11-20 JP JP2020193338A patent/JP7372897B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021038251A5 (enExample) | ||
| Kolawole et al. | In situ gelling drug delivery systems for topical drug delivery | |
| AU2010221438B2 (en) | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye | |
| JP7460707B2 (ja) | ポリアフロンおよびその眼瞼投与 | |
| Chittasupho et al. | Stability, cytotoxicity, and retinal pigment epithelial cell binding of hyaluronic acid-coated PLGA nanoparticles encapsulating lutein | |
| JP4294252B2 (ja) | Ｇリッチなアルギン酸含有組成物 | |
| JP2004196787A (ja) | 結膜下デポによるドラッグデリバリーシステム | |
| TW201442713A (zh) | 醫藥配方 | |
| KR20170105610A (ko) | 안과용 현탁액 조성물 | |
| JP7716115B2 (ja) | 薬剤送達用生体溶解性医薬ゲル | |
| JP2010534201A (ja) | 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤 | |
| JP2017501184A (ja) | 低減された眼圧で術後の炎症を治療するための方法 | |
| TW201907907A (zh) | 用於輸送活性劑的微粒調配物 | |
| JP2009102407A (ja) | Ｇリッチなアルギン酸含有組成物 | |
| US20210177751A1 (en) | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces | |
| JP6589099B2 (ja) | 濃縮水性アザライド製剤 | |
| CN116528903A (zh) | 眼用组合物 | |
| US20220040166A1 (en) | Methods and Compositions of Treating an Ophthalmic Condition | |
| WO2025144421A1 (en) | Aqueous nanomicelle ophthalmic formulations containing difluprednate | |
| JP7106852B2 (ja) | 懸濁型外用液剤 | |
| WO2017007609A1 (en) | Ocular treatment with reduced intraocular pressure | |
| CN107638384A (zh) | 经皮递送生理活性物质的水性体系及其技术 | |
| Bravo-Osuna et al. | Drug Delivery Systems for the Treatment of Diseases Affecting the Retina and Optic Nerve | |
| JP2013103919A (ja) | クロルフェニラミンマレイン酸塩を含有する徐放性フィルム製剤 | |
| FR3152980A1 (fr) | Composition ophtalmique utile notamment pour l’administration de principes actifs peu hydrosolubles ou peu stables dans l’eau |